×

Cellectis SA (Nasdaq: CLLS) to Ring The Nasdaq Stock Market Opening Bell in Celebration of IPO

ADVISORY, Mar. 25, 2015 (GLOBE NEWSWIRE) --

What:

Cellectis SA (Nasdaq:CLLS), a pioneering gene-editing company focused on developing immunotherapies, will visit the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO), which will occur today, March 25.

In honor of the occasion, André Choulika, Chief Executive Officer and Chairman will ring the Opening Bell.

Where:

Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Wednesday, March 25, 2015 – 9:15 a.m. to 9:30 a.m. ET

Cellectis SA Media Contact:

Jennifer Moore

(914) 548-5581

jennifer.moore@cellectis.com

Nasdaq MarketSite:

Christine Barna

(646) 441-5310

Christine.Barna@nasdaq.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:

http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page:

http://instagram.com/nasdaq

For news tweets, please visit our Twitter page at:

http://twitter.com/nasdaq

For exciting viral content and ceremony photos visit Tumblr Page:

http://nasdaq.tumblr.com/

Webcast:
A webcast of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.

About Cellectis (Nasdaq:CLLS):

Cellectis is a gene-editing company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company’s mission is to develop a new generation of cancer therapies based on engineered T‑cells. Cellectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN™ products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis is listed on the Nasdaq market (ticker:CLLS) and on the NYSE Alternext market (ticker: ALCLS).

About Nasdaq:

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of over $9.1 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaq.com/ambition or www.business.nasdaq.com.

-NDAQA-

Source:The NASDAQ OMX Group, Inc.